Úspěšná terapie pacienta s těžkou plakovou psoriázou risankizumabem
| Title in English | Risankizumab in successful treatment of patient with plaque psoriasis |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | FARMAKOTERAPEUTICKÁ REVUE |
| MU Faculty or unit | |
| Citation | |
| Web | https://farmakoterapeutickarevue.cz/cs/uspesna-terapie-pacienta-s-tezkou-plakovou-psoriazou-risankizumabem |
| Keywords | psoriasis; risankizumab; efficacy; safety |
| Description | Psoriasis in a chronic systemic inflammatory disease which affects 2-3% of patients. Risankizumab is a humanized, monoclonal IgG1 class antibody whose action is based on binding to the p19 subunit of interleukin 23 (IL-23). It is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic treatment. It is indicated alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adults with insufficient efficacy or intolerance to one or more nonbiologic disease-modifying antirheumatic drugs (DMARD). As the newest indication, risankizumab is the first and only IL-23 inhibitor approved by the European Medicines Agency (EMA) as of November 2022 for the treatment of moderate to severe active Crohn's disease. Risankizumab has high and durable efficacy consistent in all types of patients, regardless the predeceasing treatments and having a favorable safety at the same time. |